Spero Therapeutics, Inc. SPRO NASDAQ

Spero Therapeutics, Inc. (SPRO) generated $-8.35M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $-8.35M.

Free cash flow margin was -21.1% of revenue. Cash conversion ratio was -0.26x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (50/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
• INCOME (55/100) — Cash conversion ratio was -0.26x suggests some earnings are non-cash items

Overall SharesGrow Score: 61/100 with 2/7 criteria passed.